Cargando…
Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
Denosumab is a RANK-L inhibitor used off-label as a treatment for a variety of pediatric bone disorders, including aneurysmal bone cysts (ABC). Rebound hypercalcemia is a known side effect after denosumab therapy and is more commonly reported in pediatric patients. Although there are no established...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612474/ https://www.ncbi.nlm.nih.gov/pubmed/37908209 http://dx.doi.org/10.1210/jcemcr/luad133 |